Table 1 Ongoing clinical trials evaluating the combinatory use of epigenetic drugs and PD-1/PD-L1 immunotherapy
Trial number | Official title | Indication | Study Type |
|---|---|---|---|
NCT04722952 | PD-1 inhibitor combined with azacytidine and homoharringtonine, cytarabine, G-CSF for refractory or relapsed AML | Leukemia, AML | Phase 3 |
NCT04514081 | The clinical trial of chidamide + decitabine + camrelizumabversusdecitabine + camrelizumab in anti-PD-1 antibody resistant patients with classical hodgkin lymphoma | Hodgkin lymphoma | Phase 2 |
NCT04510610 | Camrelizumab plus decitabine in anti-PD-1 treatment-naive patients with relapsed/refractory classical hodgkin lymphoma | Hodgkin lymphoma | Phase 2 Phase 3 |
NCT03250962 | SHR−1210 alone or in combination with decitabine in relapsed or refractory Hodgkin lymphoma | Hodgkin lymphoma | Phase 2 |
NCT04353479 | PD-1 inhibitor and decitabine combination in elderly patients with relapse and refractory acute myeloid leukemia | Acute myeloid leukemia | Phase 2 |
NCT04651127 | Anti-PD-1 antibody combined with histone deacetylase inhibitor in patients with advanced cervical cancer | Cervical cancer | Phase 1 Phase 2 |
NCT04512534 | Sintilimab combined with chidamide in treating peripheral T cell lymphoma | Peripheral T-cell lymphoma | Phase 2 |
NCT02936752 | Testing the safety and efficacy of the combination of the antibody pembrolizumab and entinostat in patients with myelodysplastic syndrome who are not responding to hypomethylating agents | Myelodysplastic syndrome | Phase 1 |
NCT04514081 | The clinical trial of chidamide + decitabine + camrelizumab versus decitabine + camrelizumab in anti-PD-1 antibody resistant patients with classical hodgkin lymphoma. | Hodgkin lymphoma | Phase 2 |
NCT04038411 | PD-1 antibody, chidamide, lenalidomide, and etoposide for relapsed or refractory NK/T Cell lymphoma | NK/T cell lymphoma | Phase 4 |
NCT04040491 | PD-1 antibody, chidamide, lenalidomide and gemcitabine for peripheral T-cell lymphoma | Peripheral T-cell lymphoma | Phase 4 |
NCT03993626 | A trial of CXD101 in combination with nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL) | Malignant colorectal neoplasms | Phase 1 Phase 2 |
NCT03765229 | An exploratory study of pembrolizumab plus entinostat in non-inflamed stage III/IV melanoma | Melanoma | Phase 2 |
NCT01928576 | Phase II anti-PD1 epigenetic therapy study in NSCLC (NA_00084192) | Non-small cell lung cancer | Phase 2 |
NCT04708470 | Phase I/II trial of the combination of bintrafusp alfa (M7824), entinostat, and NHS-IL12 (M9241) in patients with advanced cancer | Metastatic solid tumor | Phase 1 Phase 2 |
NCT03250273 | A clinical trial of entinostat in combination with nivolumab for patients with previously treated unresectable or metastatic cholangiocarcinoma and pancreatic adenocarcinoma | Pancreatic cancer | Phase 2 |
NCT03161223 | Phase 1/2a study of anti-PD-L1 monoclonal antibody durvalumab in combination with pralatrexate and romidepsin, oral 5-aza and romidepsin, romidepsin alone, or oral 5-azacitidine for treatment of patients with relapsed and refractory PTCL | T-cell lymphoma | Phase 1 Phase 2 |